Hanrahan Jessie 4

4 · Solid Biosciences Inc. · Filed Apr 21, 2026

AI-generated summary of this filing

Updated Apr 21, 2026

Solid Biosciences (SLDB) CRO Jessie Hanrahan Receives Award

What Happened

Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences (SLDB), was granted 54,925 restricted stock units (RSUs) reported as an award (code A) on January 29, 2026. The filing shows an acquisition price of $0.00 and a reported value of $0 for this derivative award. This was an award of contingent/derivative securities rather than an open‑market purchase or sale.

Key Details

Transaction date: 2026-01-29; Filing date (Form 4 accession): 2026-04-21 (appears late versus the usual 2‑business‑day Form 4 requirement).
Transaction type/code: Award/Grant (A); instrument: RSUs (derivative).
Shares involved: 54,925 RSUs granted; reported acquisition price: $0.00; total reported value: $0.
Shares owned after transaction: Not specified in the provided extract — see the Form 4 for post‑transaction holdings.
Relevant footnotes:
- F1: Each RSU is a contingent right to receive one share of common stock.
- F2: These RSUs stem from performance stock units (PSUs) originally granted June 11, 2024. PSUs vest in four 25% tranches upon achievement of board‑certified, non‑market, non‑financial performance milestones. The second milestone was certified met on Jan 29, 2026; shares tied to that milestone will vest only if the grantee remains in service on the Evaluation Date (anticipated in Q1 2027).

Context

These awards are performance‑contingent RSUs, not immediate share deliveries. They only convert into actual shares if vesting and service conditions are satisfied at the later Evaluation Date. Such derivative grants are routine compensation and do not by themselves signal an immediate buy or sell by the insider.

Form 4

Period: 2026-01-29

Chief Regulatory Officer

Transactions

Award
Restricted Stock Units
[F1][F2]
2026-01-29+54,925→ 54,925 total
→ Common Stock (54,925 underlying)

Footnotes (2)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
[F2]Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Signature

/s/ Kimberly Cornwell as attorney-in-fact for Jessie Hanrahan|2026-04-21

1 file